Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $26

Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAY

0.00

Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ: RLAY) with a Market Outperform and raises the price target from $21 to $26.